MX2020010148A - Compuesto heterocíclico y su uso. - Google Patents

Compuesto heterocíclico y su uso.

Info

Publication number
MX2020010148A
MX2020010148A MX2020010148A MX2020010148A MX2020010148A MX 2020010148 A MX2020010148 A MX 2020010148A MX 2020010148 A MX2020010148 A MX 2020010148A MX 2020010148 A MX2020010148 A MX 2020010148A MX 2020010148 A MX2020010148 A MX 2020010148A
Authority
MX
Mexico
Prior art keywords
heterocyclic compound
present
migraine
behavioral
dementia
Prior art date
Application number
MX2020010148A
Other languages
English (en)
Spanish (es)
Inventor
Satoshi Mikami
Shinji Nakamura
Taku Kamei
Shigemitsu Matsumoto
Shinji Morimoto
Masaki Daini
Mitsuhiro Ito
Minoru Nakamura
Makoto Kamata
Satoshi Yamamoto
Kazuaki Takami
Masataka Murakami
Norihito Tokunaga
Jumpei Aida
Yuya Oguro
Masaki Seto
Taisuke Tawaraishi
Yasufumi Wada
Takeshi Wakabayashi
Sachie Takashima
Hiroyuki Kakei
Kouichi Iwanaga
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020010148A publication Critical patent/MX2020010148A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2020010148A 2018-03-28 2019-03-27 Compuesto heterocíclico y su uso. MX2020010148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018062939 2018-03-28
PCT/JP2019/014901 WO2019189945A1 (en) 2018-03-28 2019-03-27 Heterocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
MX2020010148A true MX2020010148A (es) 2020-12-07

Family

ID=66397395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010148A MX2020010148A (es) 2018-03-28 2019-03-27 Compuesto heterocíclico y su uso.

Country Status (17)

Country Link
US (2) US10807987B2 (https=)
EP (1) EP3774800B1 (https=)
JP (1) JP7279067B2 (https=)
KR (1) KR20200136957A (https=)
CN (1) CN111936495A (https=)
AR (1) AR115020A1 (https=)
AU (1) AU2019241765B2 (https=)
BR (1) BR112020018238A2 (https=)
CA (1) CA3100133A1 (https=)
EA (1) EA202092294A1 (https=)
ES (1) ES3006012T3 (https=)
IL (1) IL276912A (https=)
MA (1) MA52214A (https=)
MX (1) MX2020010148A (https=)
SG (1) SG11202008519RA (https=)
TW (1) TW202003519A (https=)
WO (1) WO2019189945A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3660003B1 (en) 2017-07-28 2024-01-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10807987B2 (en) * 2018-03-28 2020-10-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5252563A (en) * 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
JP3439551B2 (ja) * 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
WO2002080928A1 (en) * 2001-04-03 2002-10-17 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004161716A (ja) * 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk阻害剤
MXPA05010824A (es) * 2003-04-10 2005-12-05 Pfizer Compuestos biciclicos como antagonistas del receptor nr2b.
EP1919872A4 (en) 2005-08-31 2009-08-05 Smithkline Beecham Corp CHEMICAL COMPOUNDS
MX2011008276A (es) * 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
ES2581848T3 (es) * 2011-04-05 2016-09-07 Pfizer Limited Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6827757B2 (ja) 2016-10-11 2021-02-10 鬼怒川ゴム工業株式会社 ウエザーストリップ取付用クリップ
EP3660003B1 (en) * 2017-07-28 2024-01-24 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10807987B2 (en) * 2018-03-28 2020-10-20 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020153414A1 (ja) * 2019-01-24 2020-07-30 武田薬品工業株式会社 複素環化合物及びその用途
WO2020196828A1 (ja) * 2019-03-28 2020-10-01 武田薬品工業株式会社 含窒素複素環化合物

Also Published As

Publication number Publication date
EP3774800C0 (en) 2024-11-13
WO2019189945A1 (en) 2019-10-03
AU2019241765A8 (en) 2021-02-18
TW202003519A (zh) 2020-01-16
ES3006012T3 (en) 2025-03-17
US20190300536A1 (en) 2019-10-03
KR20200136957A (ko) 2020-12-08
WO2019189945A8 (en) 2020-10-15
EA202092294A1 (ru) 2021-01-15
US10807987B2 (en) 2020-10-20
IL276912A (en) 2020-10-29
US20210332053A1 (en) 2021-10-28
MA52214A (fr) 2021-04-21
JP2021519294A (ja) 2021-08-10
JP7279067B2 (ja) 2023-05-22
CN111936495A (zh) 2020-11-13
AR115020A1 (es) 2020-11-18
CA3100133A1 (en) 2019-10-03
SG11202008519RA (en) 2020-10-29
AU2019241765A1 (en) 2020-11-12
US11702419B2 (en) 2023-07-18
BR112020018238A2 (pt) 2020-12-29
AU2019241765B2 (en) 2022-07-07
EP3774800A1 (en) 2021-02-17
EP3774800B1 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
MY202221A (en) Heterocyclic compound and use thereof
ZA202100208B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
PH12021551846A1 (en) Heterocyclic compound and use thereof
PH12016500531B1 (en) Compound inhibiting activities of btk and/or jak3 kinases
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
JOP20170192A1 (ar) داي نوكليوتيد حلقي
GEP20227443B (en) Magl inhibitors
MX2018010192A (es) Inhibidores de glucosidasa.
JOP20220108A1 (ar) مضادات nmda حلقية غير متجانسة
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
TWD175076S (zh) 帶件之附接件
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
MX2017007884A (es) Derivados de tiadiazol amida como inhibidores de la nadph oxidasa.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
MX2020010148A (es) Compuesto heterocíclico y su uso.
GEAP201814266A (en) Pyrazines modulators of gpr6
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
PH12020500339A1 (en) Novel compounds
WO2021214348A3 (de) Verbindungen für elektronische vorrichtungen
MX2018013324A (es) Métodos y composiciones para el tratamiento del síndrome de rett.
PL406596A1 (pl) Zastosowanie pochodnych 1-podstawionego 4-benzoilotiosemikarbazydu
UA89069U (uk) Спосіб корекції активності ферментів крові індиків за протозойних інвазій